» Articles » PMID: 28218037

Immunotoxin: A New Tool for Cancer Therapy

Overview
Journal Tumour Biol
Publisher Sage Publications
Specialty Oncology
Date 2017 Feb 21
PMID 28218037
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer is one of the main reasons of death in the most countries and in Iran. Immunotherapy quickly became one of the best methods of cancer treatment, along with chemotherapy and radiation. "Immunotoxin Therapy" is a promising way of cancer therapy that is mentioned in this field. Immunotoxins are made from a toxin attaching to an antibody target proteins present on cancer cells. The first-generation immunotoxins were made of a full-length toxin attached to whole monoclonal antibodies. But, these immunotoxins could bind to normal cells. DAB389IL2 was the first immunotoxin approved by the Food and Drug Administration. Current trends and researches are ongoing on finding proteins that in combination with immunotoxins have minimal immunogenicity and the most potency for target cell killing.

Citing Articles

GD2-targeting therapy: a comparative analysis of approaches and promising directions.

Philippova J, Shevchenko J, Sennikov S Front Immunol. 2024; 15:1371345.

PMID: 38558810 PMC: 10979305. DOI: 10.3389/fimmu.2024.1371345.


In vitro and in vivo anti-tumor effect of Trichobakin fused with urokinase-type plasminogen activator ATF-TBK.

Pham D, Pham T, Bui T, Britikova E, Britikov V, Bocharov E Mol Biol Rep. 2024; 51(1):130.

PMID: 38236367 DOI: 10.1007/s11033-023-09036-6.


Hosts and Heterologous Expression Strategies of Recombinant Toxins for Therapeutic Purposes.

di Leandro L, Colasante M, Pitari G, Ippoliti R Toxins (Basel). 2023; 15(12).

PMID: 38133203 PMC: 10748335. DOI: 10.3390/toxins15120699.


Novel Anti-Mesothelin Nanobodies and Recombinant Immunotoxins with Exotoxin Catalytic Domain for Cancer Therapeutics.

Nguyen M, Kim D, Shim H, Ta H, Vu T, Nguyen T Mol Cells. 2023; 46(12):764-777.

PMID: 38052492 PMC: 10701305. DOI: 10.14348/molcells.2023.0155.


Enhanced Vaccine Immunogenicity Enabled by Targeted Cytosolic Delivery of Tumor Antigens into Dendritic Cells.

Truex N, Rondon A, Rossler S, Hanna C, Cho Y, Wang B ACS Cent Sci. 2023; 9(9):1835-1845.

PMID: 37780364 PMC: 10540291. DOI: 10.1021/acscentsci.3c00625.